Abstract
The SARS-CoV-2 pandemic virus is consistently evolving with mutations within the receptor binding domain (RBD)1 being of particular concern2-4. To date, there is little research into protection offered following vaccination or infection against RBD mutants in emerging variants of concern (UK3, South African5, Mink6 and Southern California7). To investigate this, serum and saliva samples were obtained from groups of vaccinated (Pfizer BNT-162b28), infected and uninfected individuals. Antibody responses among groups, including salivary antibody response and antibody binding to RBD mutant strains were examined. The neutralization capacity of the antibody response against a patient-isolated South African variant was tested by viral neutralization tests and further verified by an ACE2 competition assay. We found that humoral responses in vaccinated individuals showed a robust response after the second dose. Interestingly, IgG antibodies were detected in large titers in the saliva of vaccinated subjects. Antibody responses showed considerable differences in binding to RBD mutants in emerging variants of concern. A substantial reduction in RBD binding and neutralization was detected for the South African variant. Taken together our data reinforces the importance of administering the second dose of Pfizer BNT-162b2 to acquire high levels of neutralizing antibodies. High antibody titers in saliva suggest that vaccinated individuals may have reduced transmission potential. Substantially reduced neutralization for the South African variant highlights importance of surveillance strategies to detect new variants and targeting these in future vaccines.
Competing Interest Statement
T.R.W., P.K., N.S.M. and U.R. are named as inventors on a patent application (EP 20 197 031.6) claiming the use of the described Nanobodies used in the NeutrobodyPlex for diagnosis and therapeutics filed by the Natural and Medical Sciences Institute. The other authors declare no competing interest.
Funding Statement
This work was financially supported by the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Housing Construction (grant numbers FKZ 3-4332.62-NMI-67 and FKZ 3-4332.62-NMI-68), the Ministerium for Wissenschaft und Kunst Baden-Wuerttemberg, the Initiative and Networking Fund of the Helmholtz Association of German Research Centres (grant number SO-96), the Deutsche Forschungsgemeinschaft (DFG-KO 3884/5-1) and the EU Horizon 2020 research and innovation programme (grant agreement number 101003480-CORESMA). The funders had no role in study design, data collection, data analysis or the decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved the Ethics Committee of Eberhard Karls University and the University Hospital Tuebingen under the approval number 312/2020BO1 (Coro-Buddy) to Dr. Andrea Kreidenweiss, Institute for Tropical Medicine, University Hospital Tuebingen and Eberhard Karls University Tuebingen, and 312/2020BO2 to Dr. Karina Althaus, Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen . All participants gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact Information Nicole Schneiderhan-Marra – Phone number +49 (0)7121 51530 815. Postal Address – Markwiesenstrasse 55, 72770 Reutlingen, Germany.
Michael Schindler – Phone number +49 (0)7071 295790. Email Address Michael.Schindler{at}med.uni-tuebingen.de Postal Address – Elfriede-Aulhorn-Strasse 6, 72076 Tübingen, Germany
Ulrich Rothbauer – Phone number +49 (0)7121 51530 415. Email Address Ulrich.rothbauer{at}nmi.de Postal Address – Markwiesenstrasse 55, 72770 Reutlingen, Germany
Competing Interests T.R.W., P.K., N.S.M. and U.R. are named as inventors on a patent application (EP 20 197 031.6) claiming the use of the described Nanobodies used in the NeutrobodyPlex for diagnosis and therapeutics filed by the Natural and Medical Sciences Institute. The other authors declare no competing interest.
Data Availability
The original data, figure files and data analysis scripts are available upon request.
